J Drugs Dermatol. 2024 Sep 1;23(9):774-781. doi: 10.36849/JDD.8365.
Cutaneous melanoma (CM) is associated with a higher mortality rate than most other skin cancers. The purpose of this expert consensus panel was to review the published literature on new technological advancements for the diagnosis and prognosis for CM and provide updated guidance on their usage.
A comprehensive literature search of PubMed, Scopus, and Google Scholar was completed for English-language original research articles on the topics of non-invasive diagnostic and prognostic testing for CM, including gene expression profiling (GEP) and electrical impedance spectroscopy (EIS). A panel of 10 dermatologists with significant expertise in the treatment of CM gathered to review the articles and create consensus statements. A modified Delphi process was used to approve each statement and a strength of recommendation was assigned using widely recognized Strength of Recommendation Taxonomy criteria.
The literature search produced 200 articles that met the criteria. A screening of the studies resulted in 19 articles. These were distributed to all panelists for review prior to a roundtable discussion. The panel unanimously voted to adopt 7 consensus statements and recommendations, 5 of which were given a strength of "A", 1 of which was given a strength of "B," and 1 of which was given a strength of "C".
The 2-GEP test and EIS can aid in the precise diagnosis of clinically indeterminate lesions and the 23-GEP test can be used when histopathology is equivocal. The 31-GEP test can enhance prognostic assessment beyond AJCC8 staging and improve clinical decision-making. J Drugs Dermatol. 2024;23(9):774-781. doi:10.36849/JDD.8365R1.
与大多数其他皮肤癌相比,皮肤黑色素瘤(CM)的死亡率更高。本专家共识小组的目的是回顾有关 CM 的新诊断和预后新技术的已发表文献,并提供其使用的最新指南。
对 PubMed、Scopus 和 Google Scholar 进行了全面的文献检索,以查找有关 CM 的非侵入性诊断和预后检测的英文原始研究文章,包括基因表达谱(GEP)和电阻抗光谱(EIS)。一个由 10 名皮肤科医生组成的小组,他们在 CM 的治疗方面具有丰富的专业知识,聚集在一起审查这些文章并制定共识声明。使用广泛认可的推荐强度分类标准,采用改良 Delphi 流程对每个声明进行批准,并分配推荐强度。
文献检索产生了 200 篇符合标准的文章。对这些研究进行筛选后,有 19 篇文章入选。这些文章分发给所有小组成员进行审查,然后进行小组讨论。小组一致投票通过了 7 项共识声明和建议,其中 5 项具有“强烈推荐”的强度,1 项具有“中度推荐”的强度,1 项具有“弱推荐”的强度。
2-GEP 测试和 EIS 可帮助精确诊断临床不确定病变,当组织病理学不确定时可以使用 23-GEP 测试。31-GEP 测试可以增强 AJCC8 分期之外的预后评估,并改善临床决策。皮肤病药物杂志。2024;23(9):774-781.doi:10.36849/JDD.8365R1.